© 2022 MJH Life Sciences and Dermatology Times and Multimedia Medical, LLC. All rights reserved.
© 2022 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
January 18, 2022
The FDA approved the topical JAK1/JAK2 inhibitor ruxolitinib for the treatment of mild to moderate atopic dermatitis in September 2021.
Treating these patients can be a challenge, but it can also be ‘as easy as pie’ if you follow these tips.
One of the key differences between diagnosing AD in patients with skin of color compared to White skin is erythema.
AAD vice president challenges dermatologists to advocate for their patients and themselves.
January 17, 2022
Targeting skin care regimens to the individual patient is most likely to yield compliance to a recommended routine.
More trustworthy sources of information, and data, are needed.
As skin manifestations are commonly the first thing spotted with infectious disease, dermatologists are in a great position to counsel patients about prevention.
January 16, 2022
Studies offer positive outcomes for patients with conditions like hidradenitis suppurativa or psoriasis.
Sunscreen advice, recruiting during the “Great Recession”, and tips for the office led the busy agenda at Winter Clinical Dermatology Conference this weekend.
January 14, 2022
Several talks expected to focus on the latest treatment updates, as well as some recently published data on COVID-19 symptoms and a commonly-used atopic dermatitis treatment.